Physician profile
David E Blas Boria
NPI 1366642332
$14,919.36
in general payments reported to CMS, 2019-2025
23 companies · $3,251 in 2025
The $3,251 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,791 · 2020: $2,960 · 2021: $1,586 · 2022: $956 · 2023: $2,646 · 2024: $1,730 · 2025: $3,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,825 · Food and Beverage: $3,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,825.00 |
| Food and Beverage | $3,802.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $4,737.10 | 2019-2025 | Optune, Optune Gio |
| Abbvie INC. | $4,327.72 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $1,515.30 | 2019-2025 | Ajovy, Austedo Xr |
| Biogen, INC. | $833.38 | 2019-2023 | Tysabri |
| Emd Serono, INC. | $711.30 | 2022-2024 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $375.00 | 2024-2025 | |
| Genentech USA, INC. | $364.32 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $272.26 | 2021 | |
| Lundbeck LLC | $249.98 | 2024-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $230.17 | 2019-2024 | |
| Allergan, INC. | $209.51 | 2019-2021 | |
| Genzyme Corporation | $182.08 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $152.63 | 2019-2021 | |
| Genentech, INC. | $150.00 | 2025 | Ocrevus |
| Pbg Puerto Rico LLC | $135.62 | 2023-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $125.13 | 2025 | Illuccix |
| Banner Life Sciences, LLC | $124.95 | 2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $65.40 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.60 | 2022 | |
| Puma Biotechnology, INC. | $44.77 | 2022 | |
| Lilly USA, LLC | $24.05 | 2019 | |
| Tris Pharma INC | $21.50 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David E Blas Boria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.